Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer

Tristan M. Sissung; Silja Thordardottir; Erin R. Gardner; William D. Figg

doi:10.2174/187152009789735017

Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer

Tristan M. Sissung, Silja Thordardottir, Erin R. Gardner, William D. Figg

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate.

Original language	English
Pages (from-to)	1058-1069
Number of pages	12
Journal	Anti-Cancer Agents in Medicinal Chemistry
Volume	9
Issue number	10
DOIs	https://doi.org/10.2174/187152009789735017
State	Published - 2009
Externally published	Yes

Keywords

Angiogenesis inhibition
CC-5013
Lenalidomide
Prostate cancer
Thalidomide

Access to Document

10.2174/187152009789735017

Cite this

@article{17192889a93845d8ab863f7c93d05fd9,

title = "Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer",

abstract = "Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate.",

keywords = "Angiogenesis inhibition, CC-5013, Lenalidomide, Prostate cancer, Thalidomide",

author = "Sissung, {Tristan M.} and Silja Thordardottir and Gardner, {Erin R.} and Figg, {William D.}",

year = "2009",

doi = "10.2174/187152009789735017",

language = "English",

volume = "9",

pages = "1058--1069",

journal = "Anti-Cancer Agents in Medicinal Chemistry",

issn = "1871-5206",

number = "10",

}

TY - JOUR

T1 - Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer

AU - Sissung, Tristan M.

AU - Thordardottir, Silja

AU - Gardner, Erin R.

AU - Figg, William D.

PY - 2009

Y1 - 2009

N2 - Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate.

AB - Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate.

KW - Angiogenesis inhibition

KW - CC-5013

KW - Lenalidomide

KW - Prostate cancer

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=73349134659&partnerID=8YFLogxK

U2 - 10.2174/187152009789735017

DO - 10.2174/187152009789735017

M3 - Review article

C2 - 19719457

AN - SCOPUS:73349134659

SN - 1871-5206

VL - 9

SP - 1058

EP - 1069

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

IS - 10

ER -

Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this